Personal Care Products
Early In vitro screening for genotoxicity
- Saves money and improves productivity
- Enables chemists to modify compounds to reduce genotoxicity without losing desirable properties
- Scalable for high throughput testing of large collections of compounds
- GreenScreen HC and BlueScreen HC offer access to GADD45a up-regulation information
Further assays to understand the causes of positive results
- Follow up assays available
- Additional information to supplement early testing approach
Personal care testing
Personal care is one of the most attractive sectors for the chemical industry. Global sales of finished products are exceeding $300 billion at the retail level, realising global growth of at least 4.6% per year over the five year period (2004-09).
Key drivers for the industry are product diversity, competition and growing market share to serve a greater proportion of the world population currently estimated to grow to 7.6Bn by 2020.
The personal care product range is extensive covering personal hygiene as well as cosmetics.
Ensuring product safety is a continual priority for the industry and as part of this programme of safety assessment it is a requirement to test components of finished products for genotoxicity (the potential of a chemical or substance to damage or interfere with DNA).
Such testing becomes more expensive the later it occurs in the process of developing a new product candidate and so early detection of toxic liability is important.
You should also see the sector section on FFTE as it pertains to fragrance materials, which are important components of personal care products.
When to Screen
Early liability detection helps greatly and ensures product discovery budget is directed towards compounds that are safe. Finding out late in the product development process that you have a genotoxicity problem delays product delivery and can cost more due to the necessity for additional expensive testing.
The very high levels of both sensitivity and specificity achieved with GreenScreen HC and BlueScreen HC, provides a valuable insight into genotoxicity liability; often at a very early screening stage in compound development. This represents a direct and very important benefit when considering the essential requirement to provide laboratory and manufacturing staff personal protection in terms of Health and Safety.